Gilder Gagnon Howe & Co. LLC cut its stake in DexCom Inc. (NASDAQ:DXCM) by 2.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 786,047 shares of the medical device company’s stock after selling 21,073 shares during the period. DexCom comprises 1.2% of Gilder Gagnon Howe & Co. LLC’s portfolio, making the stock its 26th largest position. Gilder Gagnon Howe & Co. LLC owned about 0.94% of DexCom worth $62,357,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Tocqueville Asset Management L.P. boosted its stake in shares of DexCom by 40.9% in the second quarter. Tocqueville Asset Management L.P. now owns 21,695 shares of the medical device company’s stock valued at $1,721,000 after buying an additional 6,300 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its stake in shares of DexCom by 0.5% in the second quarter. Public Employees Retirement Association of Colorado now owns 19,466 shares of the medical device company’s stock valued at $1,544,000 after buying an additional 94 shares during the last quarter. Sit Investment Associates Inc. boosted its stake in shares of DexCom by 82.8% in the second quarter. Sit Investment Associates Inc. now owns 21,200 shares of the medical device company’s stock valued at $1,682,000 after buying an additional 9,600 shares during the last quarter. Calamos Advisors LLC purchased a new stake in shares of DexCom during the second quarter valued at about $22,764,000. Finally, American Century Companies Inc. boosted its stake in shares of DexCom by 7.3% in the second quarter. American Century Companies Inc. now owns 806,639 shares of the medical device company’s stock valued at $63,991,000 after buying an additional 54,684 shares during the last quarter. Institutional investors and hedge funds own 99.28% of the company’s stock.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Shares of DexCom Inc. (NASDAQ:DXCM) traded up 0.04% during trading on Wednesday, reaching $82.55. The company’s stock had a trading volume of 343,039 shares. DexCom Inc. has a 12 month low of $47.92 and a 12 month high of $96.38. The company’s market capitalization is $6.92 billion. The company’s 50-day moving average is $89.12 and its 200-day moving average is $78.97.

DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.12. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The firm earned $137.30 million during the quarter, compared to the consensus estimate of $132.48 million. During the same quarter last year, the firm posted ($0.05) EPS. The business’s revenue was up 47.3% on a year-over-year basis. On average, analysts forecast that DexCom Inc. will post ($0.57) EPS for the current fiscal year.

Several analysts have issued reports on DXCM shares. Deutsche Bank AG upped their price objective on DexCom from $90.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, July 15th. Jefferies Group restated a “buy” rating and set a $98.00 price objective (up previously from $90.00) on shares of DexCom in a research note on Friday, July 15th. Canaccord Genuity restated a “buy” rating and set a $95.00 price objective on shares of DexCom in a research note on Wednesday, July 13th. BTIG Research restated a “buy” rating and set a $92.00 price objective on shares of DexCom in a research note on Thursday, August 4th. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $100.00 price objective on shares of DexCom in a research note on Wednesday, August 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. DexCom currently has a consensus rating of “Buy” and a consensus price target of $95.40.

In other news, insider Terrance H. Gregg sold 10,740 shares of DexCom stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $95.29, for a total value of $1,023,414.60. Following the completion of the transaction, the insider now owns 451,486 shares in the company, valued at $43,022,100.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Terrance H. Gregg sold 10,900 shares of DexCom stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $91.03, for a total transaction of $992,227.00. Following the completion of the transaction, the insider now owns 451,486 shares of the company’s stock, valued at approximately $41,098,770.58. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by insiders.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.